Accelerating Antibody Drug Development With Subdomain-Specific Affinity Chromatography
Affinity purification platforms such as Protein A or L are well-established in the manufacturing process of therapeutic monoclonal antibodies. However, with the development of engineered modalities such as bi-specific antibodies, fragments and Fc-fusion proteins, challenges in the downstream process of these molecules arise.
Affinity chromatography resins, specifically developed to bind antibody-subdomain regions, can provide an alternative solution in the purification process of these new formats. Thereby, advancing the commercial production of new antibody therapeutics.
Download this poster to discover a solution that can:
- Perform high target purity in a single step
- Provide unique VHH screening technology to determine final resin properties
- Be suitable for cGMP manufacturing processes
Brought to you by
Download this Poster for FREE Below
Information you provide will be shared with the sponsors for this content.
Technology Networks or its sponsors may contact you to offer you content or products based on your interest in this topic. You may opt-out at any time.
